✦ LIBER ✦

The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial

✍ Scribed by Lerario, Antonio M.; Worden, Francis P.; Ramm, Carole A.; Hasseltine, Elizabeth A.; Stadler, Walter M.; Else, Tobias; Shah, Manisha H.; Agamah, Edem; Rao, Krishna; Hammer, Gary D.

Book ID: 125382708
Publisher: Springer-Verlag
Year: 2014
Tongue: English
Weight: 812 KB
Volume: 5
Category: Article
ISSN: 1868-8497
DOI: 10.1007/s12672-014-0182-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, Tolerability, Pharmacokinetics a

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study

✍ Okusaka, T.; Ikeda, M.; Fukutomi, A.; Kobayashi, Y.; Shibayama, K.; Takubo, T.; 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 157 KB